Aggressive stage I grade 1 endometrial carcinoma

Area of Science:

• Gynecologic Oncology
• Pathology
• Molecular Biology

Background:

• Stage I Grade 1 endometrial carcinoma typically has a favorable prognosis with over 90% 10-year survival.
• However, a subset of these patients experiences disease recurrence and mortality.
• Identifying prognostic factors is crucial for risk stratification.

Purpose of the Study:

• To identify clinical and histopathologic factors predicting recurrence in Stage I Grade 1 endometrial carcinoma.
• To correlate molecular markers (ER, PR, oncogenes) with disease outcome.
• To compare features of patients with fatal recurrence versus long-term survivors.

Main Methods:

• Retrospective review of 80 patients with Stage I Grade 1 endometrial carcinoma (1955-1980).
• Analysis of clinical, histopathologic, ER/PR status, DNA cytometry, and oncogene expression (c-myb, H-ras, neu).
• Comparison with 11 disease-free long-term survivors.

Main Results:

• Four adverse prognostic factors identified: myometrial invasion, vascular invasion, high mitotic rate (≥8/10 HPF), and absence of progesterone receptors (PR).
• Tumors with two or more adverse factors were associated with fatal recurrence within 4 years.
• Aneuploidy and high proliferation showed trends toward aggressive behavior but lacked statistical significance.

Conclusions:

• The presence of two or more adverse prognostic factors (myometrial invasion, vascular invasion, high mitoses, absent PR) accurately predicts early fatal recurrence in Stage I Grade 1 endometrial carcinoma.
• These factors are critical for identifying high-risk patients within this generally favorable prognostic group.